Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
Interim data demonstrate that HB‑101 is well toleratedHB-101 elicits T cell and B cell responses in the target population NEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) -- HOOKIPA...
-
NEW YORK and VIENNA, Austria, June 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases...
-
NEW YORK and VIENNA, Austria, June 17, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers...
-
NEW YORK and VIENNA, Austria, May 26, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and...
-
NEW YORK and VIENNA, Austria, May 14, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and...